Beta Bionics CPO Mike Mensinger sells $83,619 in stock

Mike Mensinger, Beta Bionics' Chief Product Officer, sold 4,375 shares of the company's stock on September 2, 2026. The sale totaled $83,619, with shares exchanged at an average price of $19.1131, ranging from $18.89 to $19.545. The stock's current price is $19.92, a significant increase from its 52-week low of $8.80, representing a 72% gain over the past six months.

The company's Pro Research Report suggests the stock might be overvalued. Mr. Mensinger used the proceeds to cover tax obligations related to the vesting of restricted stock units. Following the transaction, he directly owns 180,040 shares of Beta Bionics. Investors can explore more about the company's financial health through Beta Bionics' Pro Research Report.

In recent news, Beta Bionics reported a 38% revenue increase to $32 million in Q2 2026, but also reported a larger-than-expected loss, with earnings per share at a loss of 53 cents. Despite this, the company maintained its full-year outlook and noted improvements in its gross margin. William Blair recently initiated coverage of Beta Bionics with a Market Perform rating, praising the company's AID algorithm for the iLet insulin pump, which requires less patient interaction.